Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hearticellgram-AMI Safety Follow-up in AMI
NCT07400458Recruiting
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of Hearticellgram-AMI in acute myocardial infarction (AMI), sponsored by Pharmicell Co., Ltd. Primary endpoint: Adverse Events of Special Interest at 5 years. Started Mar 2022; status: recruiting.
02
Drugs
Hearticellgram-AMI
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT07400458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400458.